Comparative Pharmacology
Head-to-head clinical analysis: OVULEN 21 versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVULEN 21 versus PHILITH.
OVULEN-21 vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; inhibits gonadotropin release, suppressing ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet (ethinyl estradiol 0.05 mg and norethindrone 1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication.
1 mg orally once daily
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norethindrone: 5-14 hours (mean ~8 hours); terminal half-life supports once-daily dosing.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal: 50-60% as metabolites; fecal: 30-40% as conjugates; biliary excretion significant.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive